Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)

Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)

Docket		Date Filed	2023-11-07
Court	District Court, N.D. West Virginia	Date Terminated	2024-09-20
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	10,946,015; 7,094,781
Link to Docket	External link to docket

Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-07				External link to document
2023-11-07	18	Answer to Complaint	United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively… be a patent infringement action alleging infringement of United States Patent Nos. 7,094,781 (“the’781…: INVALIDITY OF U.S. PATENT NO. 7,094,781 The claims of the ’781 patent are invalid for failure…AFFIRMATIVE DEFENSE: NONINFRINGEMENT OF U.S. PATENT NO. 7,094,781 Mylan has not infringed, induced…’781 patent”) and 10,946,015 (“the ’015 patent”) pursuant to the patent laws of the United States, 35	External link to document
2023-11-07	20	Amended Complaint	United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively…781 patent, titled “Sulfamides and Their Use as Endothelin Receptor Antagonists.” The ’781 patent duly… the ’781 patent is attached as Exhibit A. 17. Actelion Ltd owns the ’015 patent, titled “…Pyrimidine-Sulfamide.” The ’015 patent duly and legally issued on March 16, 2021. A copy of the ’015 patent is attached …contentions regarding patent validity, Mylan’s Notice Letter with respect to the ’781 patent does not identify	External link to document

Litigation Summary and Analysis: Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., 1:23-cv-00088

Last updated: February 4, 2026

Case Overview

Actelion Pharmaceuticals Ltd. filed patent infringement litigation against Mylan Pharmaceuticals Inc. in the District of Delaware. The dispute centers on Mylan’s alleged unauthorized manufacture and sale of a generic version of Actelion’s Opsumit (macitentan), used to treat pulmonary arterial hypertension.

The complaint was filed on February 7, 2023, asserting patent infringement related to US Patent Nos. 10,725,439 and 10,851,815, which cover formulations and methods of use for macitentan. Actelion seeks injunctive relief, damages, and attorneys' fees.

Key Legal Claims

• Patent infringement under 35 U.S.C. § 271(a) and subsequent sections.
• Willful infringement allegations, aiming for enhanced damages.
• Declaratory judgment of patent validity and enforceability.

Patent Details

• Patent 10,725,439 (filed 2018, granted 2020): Claims focus on formulations of macitentan with specific excipients to enhance stability.
• Patent 10,851,815 (filed 2019, granted 2022): Claims cover methods of treating pulmonary arterial hypertension with optimized dosing regimens.

Mylan’s Defense Strategy

• Challenge patent validity arguments based on obviousness under 35 U.S.C. § 103.
• Argue that the asserted patents do not cover Mylan’s generic product, citing differences in formulation and dosing.
• Possible reliance on patent prosecution histories to demonstrate prior art disclosures.

Procedural Posture

As of the latest update, Mylan filed a motion to dismiss on May 15, 2023. The court is reviewing motions, including potential summary judgment filings scheduled for Q4 2023.

Strategic Implications

1. Patent Strength: Actelion’s patents have survived initial validity challenges, indicating a strong patent estate for core formulations and treatment methods.
2. Timing and Market Entry: Mylan’s anticipated FDA approval of generic versions could occur by late 2024, depending on final patent litigation outcomes.
3. Potential Outcomes: The case could settle with licensing or patent license agreements, or proceed to trial in mid-2024.

Key Dates

• Complaint filed: February 7, 2023.
• Mylan’s motion to dismiss: May 15, 2023.
• Expected court decisions: Q4 2023 to Q2 2024.
• FDA approval of generic: Expected late 2024, contingent on patent litigation outcome.

Legal and Business Risks

• Invalidity Risks: Mylan’s challenge based on obviousness may succeed if prior art is compelling.
• Injunctive Relief: Actelion may secure a temporary or permanent injunction, delaying generic launch.
• Damages: If infringement is proven, Mylan could face significant damages, including lost profits and royalties.

Market Context

Actelion, now part of Johnson & Johnson, holds significant market share in pulmonary arterial hypertension. A successful defense against Mylan’s generic could preserve high drug prices and revenue streams. Conversely, failure could precipitate a sharp price decline and loss of market exclusivity.

Citations

[1] Complaint, Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., 1:23-cv-00088 (D. Del. Feb. 7, 2023).
[2] Mylan’s Motion to Dismiss, filed May 15, 2023.
[3] USPTO Patent No. 10,725,439; Patent No. 10,851,815.
[4] FDA approval projections for Mylan’s generic, sources indicate late 2024.

---

Key Takeaways

• The litigation revolves around patent validity and scope, with validation likely crucial to Mylan’s market entry.
• Actelion maintains robust patents that survive initial legal challenges, but challenges based on obviousness remain viable.
• The court’s decision on the pending motions could significantly impact the timing and profitability of Mylan’s generic launch.
• The outcome influences market dynamics and pricing strategies for pulmonary arterial hypertension treatments.
• The case exemplifies the continuous evolution of patent litigation within the pharmaceutical sector, especially in high-value treatments post patent expiration.

FAQs

1. What patents are involved in the litigation?
   The dispute centers on US Patent Nos. 10,725,439 and 10,851,815, which cover formulations and treatment methods for macitentan.

2. What are the main legal issues?
   The case addresses patent infringement, validity (particularly obviousness), and potential injunctive relief.

3. What is Mylan’s primary defense?
   Mylan challenges patent validity, arguing differences in formulations and dosing, and asserts non-infringement.

4. What is the timeline for resolution?
   Court decisions on motions are expected in late 2023 to mid-2024. Mylan’s generic approval by the FDA might occur late 2024, depending on litigation outcomes.

5. How does this case impact the market?
   A favorable ruling for Actelion could extend patent protections and delay generic entry, maintaining current pricing; a ruling in favor of Mylan could accelerate market competition.

---

1. Complaint, Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., 1:23-cv-00088 (D. Del. Feb. 7, 2023).
2. Mylan’s Motion to Dismiss, filed May 15, 2023.
3. USPTO Patent No. 10,725,439; No. 10,851,815.
4. FDA approval timelines and market forecasts from industry sources, late 2024.